Submitted by Anonymous (not verified) on 22 April 2024 - 15:31
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 4, Status: Authorised